HUTCHMED (China) Ltd
HKEX:13
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
HK |
|
B
|
Bluebik Group PCL
SET:BBIK
|
TH |
|
Shift4 Payments Inc
NYSE:FOUR
|
US |
|
Bobst Group SA
SIX:BOBNN
|
CH |
|
S
|
Spackman Entertainment Group Ltd
SGX:40E
|
KR |
|
JW Pharmaceutical Corp
KRX:001060
|
KR |
|
Daitron Co Ltd
TSE:7609
|
JP |
|
S
|
Srithai Superware PCL
SET:SITHAI
|
TH |
|
Westlake Corp
NYSE:WLK
|
US |
|
Elliptic Laboratories ASA
OSE:ELABS
|
NO |
|
T
|
Totm Technologies Ltd
SGX:42F
|
SG |
|
Sovereign Metals Ltd
ASX:SVM
|
AU |
|
D
|
Daea TI Co Ltd
KOSDAQ:045390
|
KR |
|
Technoprobe SpA
MIL:TPRO
|
IT |
|
Surgery Partners Inc
NASDAQ:SGRY
|
US |
Wall Street
Price Targets
Price Targets Summary
HUTCHMED (China) Ltd
According to Wall Street analysts, the average 1-year price target for HUTCHMED (China) Ltd is 32.15 HKD with a low forecast of 21.61 HKD and a high forecast of 43.58 HKD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is HUTCHMED (China) Ltd's stock price target?
Price Target
32.15
HKD
According to Wall Street analysts, the average 1-year price target for HUTCHMED (China) Ltd is 32.15 HKD with a low forecast of 21.61 HKD and a high forecast of 43.58 HKD.
What is HUTCHMED (China) Ltd's Revenue forecast?
Projected CAGR
25%
For the last 14 years the compound annual growth rate for HUTCHMED (China) Ltd's revenue is 9%. The projected CAGR for the next 3 years is 25%.
What is HUTCHMED (China) Ltd's Net Income forecast?
Projected CAGR
-25%
For the last 14 years the compound annual growth rate for HUTCHMED (China) Ltd's net income is 59%. The projected CAGR for the next 3 years is -25%.
